1. Managing seborrheic keratoses: evolving strategies for optimizing patient outcomes.;Ranasinghe;J Drugs Dermatol,2017
2. Current understanding of seborrheic keratosis: prevalence, etiology, clinical presentation, diagnosis, and management.;Jackson;J Drugs Dermatol,2015
3. A-101, a proprietary topical formulation of high-concentration hydrogen peroxide solution: a randomized, double-blind, vehicle-controlled, parallel group study of the dose–response profile in subjects with seborrheic keratosis of the face.;DuBois;Dermatol Surg,2018
4. Safety and efficacy of hydrogen peroxide topical solution, 40% (w/w), in patients with seborrheic keratoses: results from 2 identical, randomized, double-blind, placebo-controlled, phase 3 studies (A-101-SEBK-301/302).;Baumann;J Am Acad Dermatol,2018
5. Approximate WAC. WAC = wholesaler acquisition cost, or manufacturer’s published price to wholesalers; WAC represents published catalogue or list prices and may not represent an actual transactional price. Source: AnalySource® Monthly. September 5, 2018. Reprinted with permission by First Databank, Inc. All rights reserved. ©2018. http://www.fdbhealth.com/policies/drug-pricing-policy.